COVID-19-associated myocarditis: single center experience of pathogenetic treatment
Article Sidebar
This work is licensed under a Creative Commons Attribution 4.0 International License.
Main Article Content
Abstract
The aim – to evaluate the effectiveness of glucocorticoid therapy in patients with myocarditis with reduced left ventricular ejection fraction that developed after COVID-19 infection.
Materials and methods. The results of glucocorticoid therapy in 32 patients aged (35.2±2.3) years with acute myocarditis after COVID-19 infection and left ventricular ejection fraction <40 % are presented. All patients were prescribed a 3-month course of methylprednisolone at a daily dose of 0.25 mg/kg, followed by a gradual dose reduction of 1 mg per week until complete withdrawal 6 months after the start of treatment.
Results and discussion. The analysis of the results of the examinations was performed in the 1st month from the onset of myocarditis to the appointment of glucocorticoids and after 6 months of observation. Six months later, the end-diastolic volume index decreased by 18.5 %, the left ventricular ejection fraction increased by 23.8 %, and the longitudinal global systolic straine increased by 39.8 %. On cardiac MRI, the number of left ventricular segments affected by inflammatory changes decreased from 6.22±0.77 to 2.89±0.45 segments, and the number of segments with fibrotic changes did not change significantly. After 6 months of treatment, there was a significant decrease in the concentrations of proinflammatory cytokines and cardiospecific antibodies.
Conclusions. The use of a 6-month course of glucocorticoid therapy in patients with myocarditis that developed after COVID-19 infection improved the contractility of the left ventricle against the background of a significant reduction in inflammatory lesions of the left ventricle and reduced concentrations of proinflammatory cytokines and cardiospecific antibodies.
Article Details
Keywords:
References
Болдуева С.А., Руслякова И.А., Захарова О.В., Рождественская М.В. Осложненное течение коронавирусной инфекции COVID-19 у пациента старческого возраста с тяжелой сердечно-сосудистой патологией // Кардиология.– 2021.– Vol. 61 (3).– P. 115–120. doi: 10.18087/cardio.2021.3.n1355.
Серцево-судинні захворювання: класифікація, стандарти діагностики та лікування / За ред. В.М. Коваленка,
М.І. Лутая, Ю.М. Сіренка, О.С. Сичова.– 4-те вид.– Київ: Моріон, 2020.– 240 с.
Сугралиев А.Б. Поражения сердца у больных COVID-19 // Кардиология.– 2020.– Vol. 61 (4).– P. 15–23. doi: 10.18087/cardio.2021.4.n1408.
Abdelnabi M., Eshak N., Saleh Y., Almaghraby A. Coronavirus Disease 2019 Myocarditis: Insights into Pathophysiology and Management // Eur. Cardiol. – 2020.– P. e51. doi: 10.15420/ecr.2020.16.
American Heart Association. HFSA/ACC/AHA statement addresses concerns re: using RAAS antagonists in COVID-19. Accessed March 20, 2020. professional.heart.org/professional/ScienceNews/UCM_505836_HFSAACCAHA-statement-addresses-concerns-re-using-RAAS-antagonists-in-COVID-19.jsp.
Argulian E., Sud K., Vogel B. et al. Right ventricular dilation in hospitalized patients with COVID-19 infection // JACC. Cardiovasc. Imaging.– 2020.– Vol. 13 (11).– P. 2459–2461. doi: 10.1016/j.jcmg.2020.05.010.
Atri D., Siddiqi H., Lang J. et al. COVID-19 for the cardiologist: a current review of the virology, Clinical Epidemiology, Cardiac and Other Clinical Manifestations and Potential Therapeutic Strategies // JACC.– 2020.– Vol. 5 (5).–
P. 518–536. doi: 10.1016/j.jacbts.2020.04.002.
Badkoubeh R.S., Khoshavi M., Laleh V. et. al. Imaging data in COVID-19 patients: focused on echocardiographic findings // Intern. J. Cardiovasc. Imaging. – 2021.– Vol. 37.– P. 1629–1636. doi: 10.1007/s10554-020-02148-1.
Bansal M. Cardiovascular disease and COVID-19 // Diabetes Metab. Syndr.– 2020.– Vol. 14 (3).– P. 247–250. doi: 10.1016/j.dsx.2020.03.013.
Beigel J.H., Tomashek K.M., Dodd L.E. et al. Remdesivir for the treatment of Covid-19 – preliminary report // New Engl. J. Med.– 2020.– Vol. 383.– P. 1813–1826. doi: 10.1056/NEJMoa2007764.
Benjamin J., Rodriguez C., Lange R.A., Mukherjee D. Gamut of cardiac manifestations and complications of COVID-19:
a contemporary review // J. Investig. Med.– 2020.– Vol. 68.– P. 1334–1340. doi: 10.1136/jim-2020-001592.
Bière L., Piriou N., Ernande L., Biederman R.W. Imaging of myocarditis and inflammatory cardiomyopathies // Arch. Cardiovasc. Dis.– 2019.– Vol. 112 (10).– P. 630–641. doi: 10.1016/j.acvd.2019.05.007.
Blyszczuk P. Myocarditis in humans and in experimental animal models // Front Cardiovasc. Med.– 2019.– Vol. 6 (64).– P. 1–17. doi: 10.3389/fcvm.2019.00064.
Caforio A.L., Pankuweit S., Arbustini E. et al. Current state of knowledge on aetiology, diagnosis, management and therapy of myocarditis: a position statement of the ESC Working group on myocardial and pericardial diseases // Eur. Heart J.– 2013.– Vol. 34 (33).– P. 2636–2648. doi: 10.1093/eurheartj/eht210.
Chen C., Zhou Y., Wang D. SARS-cov-2: A potential novel etiology of fulminant myocarditis // Herz.– 2020.– Vol. 45.– P. 230–232. doi: 10.1007/s00059-020-04909-z.
Coyle J., Igbinomwanhia E., Sanchez-Nadales A. et al. A recovered case of covid-19 myocarditis and ards treated with corticosteroids, tocilizumab, and experimental AT-001 // JACC.– 2020.– Vol. 2 (9).– P. 1331–1336.
Duarte-Neto А.N., Caldini E.G., Gomes-Gouvêa M.S. et al. An autopsy study of the spectrum of severe COVID-19 in children: From SARS to different phenotypes of MIS-C // Clin. Medicine.– 2021.– Vol. 35.– P. 100850. doi: 10.1016/j.eclinm.2021.100850.
Guan W.-J., Ni Z.-Y., Hu Y. Clinical characteristics of coronavirus disease 2019 in China // Engl. J. Medic.– 2020.– Vol. 382.– P. 1708–1720.
Guo T., Fan Y., Chen M. et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19) // JAMA Cardiol.– 2020.– Vol. 5 (7).– P. 811–818. doi: 10.1001/jamacardio.2020.1017.
Han H., Xie L., Liu R. et al. Analysis of heart injury laboratory parameters in 273 COVID-19 patients in one hospital in Wuhan, China // J. Med. Virol.– 2020.– Vol. 92.– P. 819–823. doi: 10.1002/jmv.25809.
Han Y., Chen T., Bryant J., Bucciarelli-Ducci C. et al. Society for cardiovascular magnetic resonance (SCMR) guidance for the practice of cardiovascular magnetic resonance during the COVID-19 pandemic // J. Cardiovasc. Magnetic Resonance.– 2020.– Vol. 26.
He J., Wu B., Chen Y. Characteristic electrocardiographic manifestations in patients With COVID-19 // Can. J. Cardiol.– 2020.– Vol. 36.– P. 966.e1–966.e4. doi: 10.1016/j.cjca.2020.03.028.
Hu H., Ma F., Wei X., Fang Y. Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin // Eur. Heart J.– 2021.– Vol. 42 (2).– P. 206. doi: 10.1093/eurheartj/ehaa190.
Huang C., Wang Y., Xingwang L. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China // Lancet.– 2020.– Vol. 395 (10223).– P. 497–506. doi: 10.1016/S0140-6736(20)30183-5.
Hundley G.W., Bluemke A.D., Finn P.J. et al. ACCF/ACR/AHA/ NASCI/SCMR 2010 Expert consensus document on cardiovascular magnetic resonance: a report of the American college of cardiology foundation task force on the expert consensus documents // Circulation.– 2010.– Vol. 55 (23).– P. 2614–2662. doi: 10.1016/j.jacc.2009.11.011.
Inciardi R.M., Lupi L., Zaccone G. et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19) // JAMA Cardiol.– 2020.– Vol. 5 (7).– P. 819–822. doi: 10.1001/jamacardio.2020.1096.
Januzzi J.L. Troponin and BNP use in COVID-19 – American college of cardiology. Available from: https://www.acc.org/latest-in-cardiology/articles/2020/03/18/15/25/troponin-and-bnp-use-in-covid19.
Kotecha T., Knight D.S., Razvi Y. et al. Patterns of myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic resonance // Eur. Heart J.– 2021.– Vol. 42 (19).– P. 1866–1878. doi: 10.1093/eurheartj/ehab075.
Laganà N., Marco C., Evangelista I. et al. Suspected myocarditis in patients with COVID-19.A multicenter case series // Medicine (Baltimore).– 2021.– Vol. 100 (8).– P. e24552. doi: 10.1097/MD.0000000000024552.
Maričić L., Mihić D., Sušić L., Loinjak D. COVID-19 Cardiac Complication – Myocarditis // The Open COVID J.– 2021. doi: 10.2174/2666958702101010001.
Lang M.R., Badano P.L., Mor-Avi V. et al. Recommendations for cardiac chamber quantification in adults: an update from the American Society of echocardiography and European Asssociation of cardiovascular imaging // Eur. Heart J. Cardiovasc. Imaging.– 2015.– Vol. 16 (3).– P. 233–271. doi: 10.1093/ehjci/jev014.
Li L., Huang T., Wang Y. et al. COVID-19 patients’ clinical characteristics, discharge rate, and fatality rate of meta-analysis // J. Med. Virol.– 2020.– Vol. 92 (6).– P. 577–583. doi: 10.1002/jmv.25757.
Li Y., Li H., Zhu S. et al. Prognostic value of right ventricular longitudinal strain in patients with COVID-19 // JACC Cardiovasc. Imaging.– 2020.– Vol. 13 (11).– P. 2287–2229. doi: 10.1016 / j.jcmg.2020.04.014.
Lindner D., Fitzek A., Bräuninger H. et al. Association of cardiac infection with SARS-CoV-2 in confirmed COVID-19 autopsy cases // JAMA Cardiol.– 2020.– Vol. 5 (11).– P. 1281–1285. doi: 10.1001/jamacardio.2020.3551.
Lippi G., Lavie C.J., Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): evidence from a meta-analysis // Progress Cardiovasc. Diseases.– 2020.– Vol. 63.– P. 390–391. doi: 10.1016/j.pcad.2020.03.001.
Luo P., Liu Y., Qiu L. et al. Tocilizumab treatment in COVID-19: a single center experience // J. Med. Virol.– 2020.– Vol. 92.– P. 814–818. doi: 10.1002/jmv.25801.
Madjid M., Safavi-Naeini P., Solomon S.D., Vardeny O. Potential effects of coronaviruses on the cardiovascular system: a review // JAMA Cardiol.– 2020.– Vol. 5 (7).– P. 831–840. doi: 10.1001/jamacardio.2020.1286.
Ozieranski K., Tyminska A., Jonik S. et al. Clinically Suspected Myocarditis in the Course of Severe Acute Respiratory Syndrome Novel Coronavirus-2 Infection: Fact or Fiction? // J. Card. Fail.– 2021.– Vol. 27 (1).– P. 92–96. doi: 10.1016/j.cardfail.2020.11.002.
Pirzada A., Mokhtar A.T., Moeller A.D. COVID-19 and Myocarditis: What Do We Know So Far? // CJC Open. – 2020.– Vol. 2 (4).– P. 278–285. doi: 10.1016/j.cjco.2020.05.005.
Puntmann V.O., Carerj M.L., Wieters I. et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19) // JAMA Cardiol.– 2020. doi: 10.1001/jamacardio.2020.3557.
Sakibuzzaman M., Fariza T.T., Rahman S.M. et al. A Clinical Review of COVID-19 Associated Myocarditis. Archives of Clinical and Biomedical Research.– 2020.– Vol. 4 (5).– P. 468–480. doi: 10.26502/acbr.50170119.
Sawalha K., Abozenah M., Kadado A.J. et al. Systematic Review of COVID-19 Related Myocarditis: Insights on Management and Outcome // Cardiovasc. Revasc. Med.– 2021.– Vol. 23.– P. 107–113. doi: 10.1016/j.carrev.2020.08.028.
Shi S., Qin M., Shen B. et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China // JAMA Cardiol.– 2020.– Vol. 5 (7).– P. 802–810. doi: 10.1001/jamacardio.2020.0950.
Shi Y., Wang Y., Shao C. et al. COVID-19 infection: the perspectives on immune responses // Cell Death Differ.– 2020.– Vol. 27.– P. 1451–1454. doi: 10.1038/s41418-020-0530-3.
Singh A.K., Majumdar S., Singh R., Misra A. Role of corticosteroid in the management of COVID-19: A systemic review and a Clinician’s perspective // Sciensedirect. – 2020.– Vol. 14 (5).– P. 971–978. doi: 10.1016/j.dsx.2020.06.054.
Sugimoto T., Dulgheru R., Bernard A. et al. Echocardiographic reference ranges for normal left ventricular 2D strain: results from the EACVI NORRE study // Eur. Heart J. Cardiovasc. Imaging.– 2017.– Vol. 18 (8).– P. 833–840. doi: 10.1093/ehjci/jex140.
Szekely Y., Lichter Y., Taieb P. et al. Spectrum of Cardiac Manifestations in Coronavirus Disease 2019 (COVID-19)-a Systematic Echocardiographic Study // Circulation.–
– Vol. 142.– P. 342–353. doi: 10.1161/CIRCULATIONAHA.120.047971.
Tschöpe C., Cooper L.T., Torre-Amione G., Linthout S.V. Management of myocarditis-related cardiomyopathy in adults // Circulation Research.– 2019.– Vol. 124 (11).– P. 1568–1583. doi: 10.1161/CIRCRESAHA.118.313578.
Vaduganathan M., Vardeny O., Michel T. et al. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19 // New Engl. J. Med.– 2020.– Vol. 382.– P. 1653–1659. doi: 10.1056/NEJMsr2005760.
Varga Z., Flammer A.J., Steiger P. et al. Endothelial cell infection and endotheliitis in COVID-19 // Lancet.– 2020.– Vol. 395.– P. 1417–1418. doi: 10.1016/S0140-6736(20)30937-5/.
Wang D., Hu B., Hu C. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan. China // JAMA.– 2020.– Vol. 323.– P. 1061–1069.
Wit E., Feldmann F., Cronin J. et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection // Proc. Natl. Acad. Sci.– 2020.– Vol . 117.– P. 6771–6776.
Wu C., Chen X., Cai Y. et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China // JAMA. Intern. Med.– 2020.– Vol. 180 (7).– P. 934–943. doi: 10.1001/jamainternmed.2020.0994.
Xu Z., Shi L., Wang Y., Zhang J. et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome // The Lancet Respir. Medic.– 2020.– Vol. 8 (4).– P. 420–422. doi: 10.1016/S2213-2600(20)30076-X.
Yang C., Jin Z. An acute respiratory infection runs into the most common noncommunicable epidemic – COV.69+ID-19 and cardiovascular diseases // JAMA Cardiol.– 2020.– Vol. 5 (7).– P. 743. doi: 10.1001/jamacardio.2020.0934.
Zheng Y.Y., Ma Y.T., Zhang J.Y., Xie X. COVID-19 and the cardiovascular system // Nat. Rev. Cardiol.– 2020.– Vol. 17 (5).– P. 259–260. doi: 10.1038/s41569-020-0360-5.
Zhou F., Yu T., Du R. Clinical course and risk factors for
mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study // Lancet.– 2020.– Vol. 395.– P. 1054–1062.
Zumla A., Niederman M.S. Editorial: The explosive epidemic outbreak of novel coronavirus disease 2019 (COVID-19) and the persistent threat of respiratory tract infectious
diseases to global health security // Cur. Opinion Pulmonary Med.– 2020.– Vol. 26 (3).– P. 193–196. doi: 10.1097/MCP.0000000000000676.